|Bid||5.42 x 1200|
|Ask||6.53 x 1000|
|Day's Range||5.61 - 5.96|
|52 Week Range||1.45 - 6.50|
|Beta (3Y Monthly)||-0.50|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 6, 2019 - Mar 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.75|
NEW YORK, Nov. 27, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
CORAL GABLES, FL / ACCESSWIRE / November 19, 2018 / Healthcare stocks have rallied during the last 3 trading sessions. On Friday, the market powered higher, lead by healthcare stocks. Furthermore, the idea that a split congress could be a good thing for healthcare stocks is offering a brighter outlook for some investors to look closer at several smaller healthcare companies that could be set to rebound.
Imprimis Pharmaceuticals, Inc. (IMMY) today announced that it ranked 88th on Deloitte’s Technology Fast 500™, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies in North America. Winners were selected based on percentage fiscal year revenue growth from 2014 to 2017, and Imprimis grew 1,513% during this period. “Congratulations to the Deloitte 2018 Technology Fast 500 winners on this impressive achievement,” said Sandra Shirai, vice chairman, Deloitte LLP, and U.S. technology, media and telecommunications leader.
CORAL GABLES, FL / ACCESSWIRE / November 14, 2018 / The healthcare sector is the sector of the economy made up of companies that specialize in products and services related to health and medical care. As the industry continues to emerge as a leading place for investors to hedge against broader market volatility, companies like Premier Health Group, Inc. (PHGRF) (PHGI), ReShape Lifesciences Inc. (RSLS), Teladoc (TDOC), and Imprimis Pharmaceuticals, Inc. (IMMY). Premier Health Group, Inc. (PHGRF) (PHGI) is focused on developing innovative approaches that combine human skill based expertise with emerging technologies for the healthcare industry.
The San Diego-based company said it had a loss of 12 cents per share. The pharmaceutical and drug compounding company posted revenue of $10.7 million in the period. In the final minutes of trading on Tuesday, ...
SAN DIEGO, Nov. 13, 2018 -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) today reported results for the third quarter 2018. Third Quarter 2018 and Other Recent Notable.
Imprimis Pharmaceuticals, Inc. (IMMY) today announced it will release third quarter 2018 financial results after the close of trading on Tuesday, November 13, 2018. The company will host a conference call at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day to discuss the financial results and recent business developments. Imprimis Pharmaceuticals, Inc. (IMMY) is a commercial-stage pharmaceutical company based in San Diego, California. In addition to owning the nation’s leading ophthalmology pharmaceutical compounding business, ImprimisRx, the Company holds large equity positions in Eton Pharmaceuticals, Surface Pharmaceuticals and Melt Pharmaceuticals, companies originally founded as subsidiaries of Imprimis. The Company also owns royalty rights in certain 505(b)(2) drug candidates being developed by Eton, Surface and Melt. For more information about Imprimis, please visit the Investor Relations section of the corporate website by clicking here.
Melt Pharmaceuticals, a subsidiary of Imprimis Pharmaceuticals, Inc. (IMMY), today announced that following the presentation of clinical data on the MKO Melt® (midazolam/ketamine/ondansetron) from a 611-patient IRB approved prospective, controlled, randomized, three arm comparator study at the American Academy of Ophthalmology meeting this month, additional studies on Melt’s drug candidates will soon begin. The objective of this study is to establish the pharmacokinetics and pharmacodynamics of midazolam and ketamine following administration of the patented MK Melt in up to twenty-five healthy volunteers under an IRB approved protocol with informed consent.
NEW YORK, Oct. 16, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Since the financial collapse, the Federal Reserve — and then other nations’ central banks — took off monetary policy to make sure there wasn’t a massive global financial collapse. Interest rates are rising again and now portfolio managers are reallocating assets across stocks and bonds. Imprimis Pharmaceuticals (NASDAQ:IMMY) is a San Diego-based pharmaceutical company that specializes in compounded pharmaceuticals.
On a per-share basis, the San Diego-based company said it had net income of 12 cents. The pharmaceutical and drug compounding company posted revenue of $10.4 million in the period. In the final minutes ...
SAN DIEGO , Aug. 6, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) today reported results for the second quarter 2018. Notable Highlights from the Second Quarter of 2018: Revenues of ...
NEW YORK, NY / ACCESSWIRE / August 6, 2018 / Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 6, 2018 at 4:30 PM Eastern ...
Study to assess drug safety, patient preference and pharmacoeconomic measures in 200 routine cataract surgeries SAN DIEGO , Aug. 1, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) through ...
SAN DIEGO , July 18, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, today announced that its Chief Executive Officer, Mark L. Baum ...
SAN DIEGO, May 30, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc.'s (IMMY) ophthalmology compounding division, ImprimisRx, is pleased to announce the findings from a study published in the Journal of Cataract and Refractive Surgery in January 2018, which followed 483 eyes with glaucoma that were undergoing cataract surgery with concomitant trabecular microbypass stent insertion. The study was initially presented at the American Society of Cataract and Refractive Surgery (ASCRS) and examines post-surgery outcomes for patients receiving an intravitreal injection of steroid and antibiotics at the time of surgery compared with a standard drop regimen following surgery. All study participants were diagnosed with primary open-angle glaucoma and received a glaucoma stent at the time of surgery in parallel with the cataract surgery procedure. The study group of 234 eyes received an intravitreal injection (pars plana) of 0.2 mL of Dropless®, a combination of steroid and antibiotics, at the time of surgery. The control group of 249 eyes received a standard topical regimen postoperatively.
LONDON, UK / ACCESSWIRE / May 29, 2018 / If you want access to our free research report on Emergent BioSolutions Inc. (NYSE: EBS) ("Emergent"), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=EBS as the Company's latest news hit the wire. On May 24, 2018, the Company announced that the Coalition for Epidemic Preparedness Innovations (CEPI) has provided up to $25 million to the Company and Profectus BioSciences, Inc. ("Profectus") to advance the development and manufacture of a vaccine against the Nipah virus (NiV), a bat-borne virus that can spread to both humans and livestock. Active-Investors.com is currently working on the research report for Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), which also belongs to the Healthcare sector as the Company Emergent BioSolutions.
The San Diego-based company said it had a loss of 17 cents per share. The pharmaceutical and drug compounding company posted revenue of $8.9 million in the period. In the final minutes of trading on Tuesday, ...
SAN DIEGO, May 15, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (IMMY) today reported financial results for the first quarter 2018. Imprimis Pharmaceuticals has retained ownership of 3.5 million shares of Eton Pharmaceuticals common stock and 3.5 million shares of Surface Pharmaceuticals common stock. In addition, Imprimis owns mid-single digit royalty rights on all contributed drugs. Imprimis retains royalty rights on two patent-pending sterile injectable drug candidates contributed to Eton, one targeting infantile spasms and the other targeting Peyronie's Disease. Imprimis retains royalty rights on three patent-pending drug candidates contributed to Surface, two are topical eye drop drug candidates, the third is an oral capsule, all of which target certain ocular surface diseases.
SAN DIEGO, and PLEASANTON, Calif., May 15, 2018 /PRNewswire/ -- Surface Pharmaceuticals, Inc., an affiliated company of Imprimis Pharmaceuticals, Inc. (IMMY), today announced it has entered into a definitive stock purchase agreement with an affiliate of Flying L Partners to raise proceeds of up to approximately $20 million in a private placement of its Series A preferred stock. Surface Pharmaceuticals intends to use the proceeds of the Series A financing to advance its clinical development programs focused on ocular surface disease, including Dry Eye Disease treatments, by seeking FDA approval for three drug candidates for up to five indications, as well as for general corporate purposes.
While small-cap stocks, such as Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) with its market cap of US$47.54M, are popular for their explosive growth, investors should also be aware of their balance sheetRead More...